GEMini ™ Joint Testing and Validation with TheraView Technology by Cablon Medical B.V.

The C-RAD GEMini™ detector system has been especially designed for VMAT treatments in advanced radiation therapy. The detector will be used both as an imaging and dosimetry device.

The technical integration work has been proceeding well, and based on pre-clinical results C-RAD and Cablon Medical B.V. have agreed to move to the next phase by starting up joint testing and validation activities in collaboration with a leading radiation therapy center, UMC Utrecht in The Netherlands.

Once clinical validation has been completed, the GEMini™ system in combination with the software package from Cablon Medical will be available for unrestricted clinical use, first within the EU and later also on other markets. Marketing and sales activities have already been started up and negotiations are ongoing with a number of potential customers.

A development and mutual distribution agreement was in 2013 signed with the Dutch company TheraView Technology by Cablon Medical, B.V., giving C-RAD the rights to distribute TheraView’s well-proven software for Portal Dosimetry and Imaging together with the GEMini™ detector. Cablon is also able to offer the GEMini™ detector to its current installed base within the BeNeLux region.

Tim Thurn, CEO, C-RAD AB:

“A project to redesign the GEMini was initiated during 2013, with the aim to significantly improve both image quality and dosimetric performance. With the latest test results we conclude that this work is now completed. We are very pleased to move into a commercial phase together with our partner Cablon Medical. The cooperation with Paracelsus Medical University in Salzburg will continue.”

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666947, E-mail investors@c-rad.com

The above information is price sensitive and must therefore be disclosed under the Securities Market Act (2077:528).

About C-RAD

C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 28 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company’s first product, the C-RAD Sentinel^TM, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian  and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded three companies for direct sales, C-RAD Incorporated in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. C-RAD has invested in 29 % of the laser company Cyrpa and with an option to acquire the remaining 71 %. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier. Erik Penser Bankaktiebolag is appointed as C-RAD’s Certified Adviser.

For more information on C-RAD, please visit www.c-rad.com.